537 related articles for article (PubMed ID: 9510219)
1. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Tollefson GD; Sanger TM; Lu Y; Thieme ME
Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Breier A; Hamilton SH
Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
[TBL] [Abstract][Full Text] [Related]
5. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Tollefson GD; Sanger TM
Schizophr Res; 1999 Mar; 35 Suppl():S13-21. PubMed ID: 10190222
[TBL] [Abstract][Full Text] [Related]
6. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Tollefson GD; Sanger TM
Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
[TBL] [Abstract][Full Text] [Related]
7. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
9. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
12. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Tollefson GD; Sanger TM; Beasley CM; Tran PV
Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
15. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Tollefson GD; Andersen SW; Tran PV
Biol Psychiatry; 1999 Aug; 46(3):365-73. PubMed ID: 10435202
[TBL] [Abstract][Full Text] [Related]
16. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
17. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
18. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Tollefson GD; Andersen SW
J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
[TBL] [Abstract][Full Text] [Related]
19. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Ishigooka J; Inada T; Miura S
Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]